A randomized double-blind crossover trial suggested that Par may cause calcium and phosphorus metabolism disorder after long-term medication (Parvanova et al. 2018), but this problem exists commonly in the clinical application of VDR agonists. This evidence concerns the gene VDR and metabolic disease.